https://scholars.lib.ntu.edu.tw/handle/123456789/538600
標題: | Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: A single-center, 20-year experience | 作者: | Wang D.-S. MENG-YAO LU YUNG-LI YANG Lin D.-T. Lin K.-H. HSIU-HAO CHANG SHIANN-TANG JOU |
公開日期: | 2021 | 出版社: | Elsevier B.V. | 卷: | 120 | 期: | 1 | 起(迄)頁: | 594-601 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose: The Taiwan Pediatric Oncology Group (TPOG) initiated two consecutive protocols for treating pediatric patients with Langerhans cell histiocytosis (LCH) since 1994. However, the results have not been analyzed and reported. This study aimed to investigate the survival outcomes of childhood LCH at the National Taiwan University Hospital over the past 20 years. Methods: Treatment of pediatric patients with LCH according to TPOG protocols at the National Taiwan University Hospital began in 1994. During 1994–2003, patients were treated using the TPOG LCH-94 protocol. After 2003, patients were treated using the TPOG LCH-2003 protocol. Clinical data of these patients were obtained retrospectively by reviewing electronic medical records. Patients were followed up until July 31, 2018. Results: Fifty-three newly diagnosed pediatric patients with LCH were treated at National Taiwan University Hospital during 1994–2015. Twenty-nine (54.7%) were treated with the TPOG LCH-94 protocol, and 24 (45.3%) were treated with the TPOG LCH-2003 protocol. The 5-year event-free survival and overall survival rates were 96.2 ± 2.6% standard error (SE) and 98.1 ± 1.9% (SE), respectively. Overall survival and 5-year event-free survival between patients treated with the TPOG LCH-94 and TPOG LCH-2003 protocols showed no significant difference. Multisystem, liver, or spleen diseases were associated with significantly bad survival outcomes. Among at-risk-organ involvement in LCH, liver involvement was an independent factor for poor prognosis. Conclusion: Clinical outcomes of children with LCH in Taiwan was good. The results of this study may help in the better classification of risk grouping for protocol designs in the future. ? 2020 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088979712&doi=10.1016%2fj.jfma.2019.12.019&partnerID=40&md5=6d7c17748c13b7e656ae5b0ead55e9ec https://scholars.lib.ntu.edu.tw/handle/123456789/538600 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2019.12.019 | SDG/關鍵字: | cyclophosphamide; desmopressin; etoposide; mercaptopurine; methotrexate; prednisolone; prednisone; vinblastine; vincristine; adolescent; Article; central nervous system disease; child; childhood mortality; clinical outcome; clinical protocol; controlled study; diabetes insipidus; electronic medical record; event free survival; female; follow up; hematologic disease; hepatomegaly; high risk population; human; infant; Langerhans cell histiocytosis; liver dysfunction; major clinical study; male; newborn; nuclear magnetic resonance imaging; organs at risk; overall survival; pediatric patient; pediatrics; polyuria; prognosis; randomized controlled trial (topic); recurrent disease; retrospective study; sepsis; spine disease; spleen disease; systemic disease; systemic therapy; Taiwan; university hospital; whole body MRI; cancer staging; Langerhans cell histiocytosis; survival rate; Child; Histiocytosis, Langerhans-Cell; Humans; Neoplasm Staging; Retrospective Studies; Survival Rate; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。